Ki—67与非小细胞肺癌患者EGFR突变的关系及其对预后的影响(4)
[14] Pao W，Miller V，Zakowski M，et al. EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib [J]. Proc Nati Acad Sci U S A，2004， 101(36)：13 306-13 311.
[15] Wu YL，Zhou C，Liam CK，et al. First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer：analyses from the phase Ⅲ，randomized，open-label，ENSURE study [J]. Ann Oncol，2015，26(9)：1883.
[16] Huang HT，Chen L，Lu CX，et al. Clinical pathological significance of expression of Tspan-1，Ki67 and Cd34 in human lung cancer [J]. Acta Medica Mediterranea，2015， 31(6)：1175-1180.
[17] Romero Q，Bendahl PO，Fern？ M，et al. A novel model for Ki67 assessment in breast cancer [J]. Diagn Pathol，2014， 9(1)：1-8.
[18] Li LT，Jiang G，Chen Q，et al. Ki67 is a promising molecular target in the diagnosis of cancer (review) [J]. Mol Med Rep，2015，11(3)：1566.
[19] Dingemans AC，Van AJ，Span S，et al. Topoisomerase IIalpha and other drug resistance markers in advanced non-small cell lung cancer [J]. Lung Cancer，2001，32(2)：117-128.
[20] Li J，Chen L，Jiao SC，et al. Topoisomerase Ⅱ alpha expression and the benefit of adjuvant chemotherapy for postoperative patients with non-small cell lung cancer [J]. BMC Cancer，2010，10(1)：621., http://www.100md.com(张煜坤 戈伟)
[15] Wu YL，Zhou C，Liam CK，et al. First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer：analyses from the phase Ⅲ，randomized，open-label，ENSURE study [J]. Ann Oncol，2015，26(9)：1883.
[16] Huang HT，Chen L，Lu CX，et al. Clinical pathological significance of expression of Tspan-1，Ki67 and Cd34 in human lung cancer [J]. Acta Medica Mediterranea，2015， 31(6)：1175-1180.
[17] Romero Q，Bendahl PO，Fern？ M，et al. A novel model for Ki67 assessment in breast cancer [J]. Diagn Pathol，2014， 9(1)：1-8.
[18] Li LT，Jiang G，Chen Q，et al. Ki67 is a promising molecular target in the diagnosis of cancer (review) [J]. Mol Med Rep，2015，11(3)：1566.
[19] Dingemans AC，Van AJ，Span S，et al. Topoisomerase IIalpha and other drug resistance markers in advanced non-small cell lung cancer [J]. Lung Cancer，2001，32(2)：117-128.
[20] Li J，Chen L，Jiao SC，et al. Topoisomerase Ⅱ alpha expression and the benefit of adjuvant chemotherapy for postoperative patients with non-small cell lung cancer [J]. BMC Cancer，2010，10(1)：621., http://www.100md.com(张煜坤 戈伟)